Thursday, January 8, 2026, 7-8pET – State of the Art: Lipid SIG
Session Title:
Pediatric hypertriglyceridemia is a clinically significant and increasingly recognized condition with implications for both acute and long-term health. Pediatric endocrinologists play a key role in identifying, stratifying, and managing this lipid disorder, which may range from mild elevations to life-threatening severe hypertriglyceridemia associated with pancreatitis. Given the complex interplay between genetic, metabolic, and secondary causes, pediatric endocrine providers must be equipped with practical, pathophysiology-based approaches to diagnosis and management. Early, targeted intervention can prevent complications and reduce cardiovascular risk later in life. This case-based session will empower clinicians with actionable algorithms tailored to severity and etiology, enhancing the precision of care for affected children and adolescents.
Learning objectives:
- Evaluate hypertriglyceridemia by severity and align first-line interventions with each tier.
- Illustrate a risk-stratified algorithm that matches interventions to underlying pathophysiology
- Distinguish monogenic severe hypertriglyceridemia from multifactorial/polygenic causes and tailor therapy accordingly.
Speaker:
Ambika P. Ashraf MD, FAAP, FNLA
Ralph Frohsin Endowed Chair in Pediatric Endocrinology
Division Director/ Pediatric Endocrinology and Diabetes
Associate Director, Comprehensive Diabetes Center
Professor of Pediatrics/Heersink School of Medicine
The University of Alabama at Birmingham